Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Pradaxa Approval Balances Efficacy And Bleeding Risk

Executive Summary

Boehringer Ingelheim GmbH's breakthrough anticoagulant Pradaxa (dabigatran) will be available to physicians and patients in the "next several days," the company said after FDA cleared the drug Oct. 19.
Advertisement

Related Content

BMJ’s Pradaxa Exposé Includes Wider Call For Monitoring Of All New Anticoagulants
Xarelto Faces Approval, Labeling Obstacles Even After Cmte. Endorsement
Apixaban Shows Mortality Advantage, But Will It Survive FDA Scrutiny?
Xarelto Atrial Fibrillation Data Suggest Lines Of Advisory Committee Inquiry
Pradaxa Review Shows FDA Doubts About The Power Of REMS To Change Prescribing Practices
Oral Anticoagulants Market Snapshot: Big Bucks, But Payers Are On Guard
Oral Anticoagulants Market Snapshot: Big Bucks, But Payers Are On Guard
FDA Plays It Safe With Boehringer Ingelheim's Pradaxa By Approving A Single Dosing Option
FDA's Pradaxa Quandary: Clearing Both Doses Could Mask Dabigatran's Superiority
FDA's Pradaxa Quandary: Clearing Both Doses Could Mask Dabigatran's Superiority

Topics

Advertisement
UsernamePublicRestriction

Register

PS052751

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel